A registration trial of CPI-444 in late-stage renal cancer patients.
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2017
At a glance
- Drugs CPI 444 (Primary)
- Indications Renal cancer
- Focus Registrational; Therapeutic Use
- 11 Nov 2017 According to a Corvus Pharmaceuticals media release, this trial is expected to begin in 2018.
- 13 Jan 2017 New trial record
- 10 Jan 2017 According to a Corvus Pharmaceuticals media release, based on the positive data from Phase 1/1b trial (see profile 262434) company is planning to initiate this trial before the end of 2017.